VIM and breast carcinoma: Due to the identification of MTHFD2 as a modulator of vimentin expression in metastatic breast cancer cells and high expression associating with poor characteristics in clinical breast cancer samples, the cellular consequences of MTHFD2 impairment to metastasis relevant phenotypes were studied in more detail.